Related Experiment Video
Updated: Jun 7, 2025
Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
Published on: February 2, 2013
High-throughput screening for optimizing adoptive T cell therapies
Yuchen Zhang1, Qinglong Xu1, Zhifei Gao1
1Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, People's Republic of China.
Abstract:
Adoptive T cell therapy is a pivotal strategy in cancer immunotherapy, demonstrating potent clinical efficacy. However, its limited durability often results in primary resistance. High-throughput screening technologies, which include both genetic and non-genetic approaches, facilitate the optimization of adoptive T cell therapies by enabling the selection of biologically significant targets or substances from extensive libraries. In this review, we examine advancements in high-throughput screening technologies and their applications in adoptive T cell therapies. We highlight the use of genetic screening for T cells, tumor cells, and other promising combination strategies, and elucidate the role of non-genetic screening in identifying small molecules and targeted delivery systems relevant to adoptive T cell therapies, providing guidance for future research and clinical applications.
Insights
High-throughput screening enhances adoptive T cell therapy for cancer by identifying optimal targets and treatments. This approach improves T cell therapy
Area of Science:
- Immunotherapy
- Genomics
- Drug Discovery
Background:
- Adoptive T cell therapy is a key cancer immunotherapy with significant clinical success.
- Limited durability and primary resistance are major challenges in current T cell therapies.
- High-throughput screening (HTS) offers a powerful approach to optimize these therapies.
Purpose of the Study:
- To review advancements in HTS technologies for adoptive T cell therapy.
- To explore the application of genetic and non-genetic screening in this field.
- To guide future research and clinical applications of optimized T cell therapies.
Main Methods:
- Examination of genetic screening approaches for T cells and tumor cells.
- Review of non-genetic screening methods, including small molecule and targeted delivery systems.
- Analysis of combination strategies involving HTS and adoptive T cell therapy.
Main Results:
- HTS technologies enable selection of significant targets from large libraries.
- Genetic screening identifies key genetic factors influencing T cell efficacy.
- Non-genetic screening reveals novel small molecules and delivery systems for therapy enhancement.
Conclusions:
- HTS is crucial for optimizing adoptive T cell therapy's efficacy and durability.
- Integration of genetic and non-genetic screening strategies holds significant promise.
- This review provides a roadmap for advancing T cell therapy through HTS.
